Womens Health

Real-World Evidence Shows Cost Effectiveness of Offering NIPT to All Pregnant Women

Offering insurance coverage of non-invasive prenatal testing to all pregnant women increases utlilization at a cost of less than 3 cents per member per month.

Womens Health

Progenity Test for Triaging Preeclampsia Passes Key Development Milestone

This proprietary test is a multi-analyte protein biomarker assay which is designed to be run from a simple blood draw.

Womens Health

Perkin Elmer to Distribute Preeclampsia Detection Device

The preeclampsia detection kit is a highly accurate, urine-based, noninvasive point-of-care test, meaning no specialized instrumentation or equipment is needed.

Thermo Fisher Scientific and NX Prenatal Collaborate to Develop Fetal Health Assays

Jun 11, 2019 | Balances, Mass Spectrometry, Mass Spectrometry Instruments, Mass Spectrometry Reagents & Test Kits, Prenatal Testing, Research

Thermo Fisher and NX Prenatal will develop clinical mass spectrometry-based workflows for monitoring maternal and fetal health during pregnancy, and evaluating the risk of complications.

April 2019 Product Spotlight: Immunoassay Analyzers

May 21, 2019 | Fertility Testing, Immunoassay, Microbiology Instruments, Womens Health

April 2019’s product spotlight includes immunoassay kits and analyzers from companies such as Fujirebio, Ansh Labs, Tosoh Bioscience, and more.

April 2019 Product Spotlight: Immunoassay Analyzers

May 21, 2019 | Fertility Testing, Immunoassay, Microbiology Instruments, Womens Health

April 2019’s product spotlight includes immunoassay kits and analyzers from companies such as Fujirebio, Ansh Labs, Tosoh Bioscience, and more.

First Customizable Noninvasive Prenatal Test for Single-Gene Disorders

May 13, 2019 | Prenatal Testing, Standards

The test broadens expectant parents’ prenatal testing options to include a safe, noninvasive test tailored to their family’s risk for a specific genetic disease.

Prenatal Screening Identifies More Couples at Risk for Birth Defects

May 13, 2019 | Prenatal Testing, Research

The Foresight carrier screen identified 45% more couples at risk for having a child with cystic fibrosis than current guideline-based testing.

Next-Generation Multiplexing

Mar 27, 2019 | Microscopy, Prenatal Testing, Software

A novel multiplexing platform called ‘high definition polymerase chain reaction’ brings together widely used, low-cost chemistries and qPCR instrumentation with proprietary data science algorithms to enable streamlined multiplex test development and very affordable test deliverables.

US Study Reveals Lack of Knowledge about Heart Disease

Mar 13, 2019 | Heart Disease, Research

The nationwide study showed worrisome beliefs surrounding cardiac health and disease prevention.

Myriad’s Expanded Aneuploidy Analysis Could Improve Birth Outcomes

Feb 14, 2019 | Womens Health

Enhanced test improves detection of chromosomal abnormalities by 30%.

LGC Maine Standards Adds Cerebrospinal Fluid Total Protein to Validate Body Fluids Kit

Feb 6, 2019 | Fertility Testing, Standards, Womens Health

The addition allows for easier validation of laboratory-developed tests, documentation of linearity and calibration verification, and verification of reportable range.

Automating the Clinical Lab

Jan 31, 2019 | Electrolytes, Heart Disease, Lab Automation

The current generation of instruments for in vitro diagnostics is helping to support clinical labs through a strong emphasis on automation.

New Test Enables Resistance-Guided Therapy for Gonorrhea

Jan 31, 2019 | Fertility Testing, Infectious Diseases, Molecular Diagnostics, Sexually Transmitted Diseases, Womens Health

The ResistancePlus GC molecular diagnostic simultaneously diagnoses N. gonorrhoeae and provides antimicrobial susceptibility information, overcoming many of the issues associated with culture-based methods.

FDA Permits Marketing of First Test to Aid in the Diagnosis of Mycoplasma genitalium Infection

Jan 31, 2019 | Controls, Fertility Testing, Swabs, Womens Health

Hologic’s first-in-category assay, cleared through FDA’s De Novo review process, provides laboratories with a highly sensitive and specific molecular diagnostic method to identify M. genitalium infections and enable effective treatment.